𝔖 Bobbio Scriptorium

✦ LIBER ✦

The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer

✍ Scribed by Gebremeskel, Simon; LeVatte, Terry; Liwski, Robert S.; Johnston, Brent; Bezuhly, Michael

Book ID: 121790985
Publisher: John Wiley and Sons
Year: 2014
Tongue: French
Weight: 772 KB
Volume: 136
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.28947

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

549 POSTER The RANKL inhibitor osteoprot

549 POSTER The RANKL inhibitor osteoprotegerin (OPG) inhibits tumor growth, prevents tumor-induced osteolysis, and significantly improves survival in a mouse model of breast cancer bone metastasis

✍ J. Canon; M. Roudier; R. Bryant; R. Radinsky; W. Dougall 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 71 KB

The influence of P2Y12 receptor deficien

The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: Evidence for specific inhibition of P2Y12 receptors by prasugrel

✍ Masami Hashimoto; Atsuhiro Sugidachi; Takashi Isobe; Yoichi Niitsu; Taketoshi Og 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 485 KB

Comparison of ticagrelor, the first reve

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

✍ Stefan James; Axel Åkerblom; Christopher P. Cannon; Håkan Emanuelsson; Steen Hus 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Comparison of ticagrelor, the first reve

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

✍ Stefan James; Axel Åkerblom; Christopher P. Cannon; Håkan Emanuelsson; Steen Hus 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Rationale and design of the randomized,

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

✍ Sergio Leonardi; Sunil V. Rao; Robert A. Harrington; Deepak L. Bhatt; C. Michael 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 375 KB

Chemoprevention of intestinal polyposis

Chemoprevention of intestinal polyposis by COX-2 inhibition: From mouse to man: Ohshima M. Murai (Hata) N, Kargama S, Aguello M, Luk P, Kwong E, Taketo M, Evans JF (Banyu-Merck Research Center, Tsukuba, Japan; Merck Frosst Center for Therapeutic Research, Pointe-Claire Dorval, Quebec, Canada; University of Kyoto, Tokyo, Japan; and Merck and Co., Inc., West Point, Pennsylvania). Chemoprevention of intestinal polyposis in the Apcδ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733–1740

✍ Robert S. Bresalier 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 353 KB